DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Chan A, Moy B, Mansi J. et al. ExteNET Study Group.
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Clin Breast Cancer 2021;
21: 80-91.e7
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.